Plasma Protein Binding, Biostability, Metabolite Profiling, and CYP450 Phenotype of TPB15 Across Different Species: A Novel Smoothened Inhibitor for TNBC Therapy

Dingsheng Wen, Bo‐Yu Chen, Mingqi Deng, Shaoyu Wu, Shuilin XiePharmaceutics 2025 · DOI

TL;DR

This study investigates the pharmacokinetic properties of TPB15, a novel inhibitor targeting the Hedgehog pathway for triple-negative breast cancer (TNBC). TPB15 demonstrates consistent plasma protein binding and stability across multiple species, with metabolism primarily driven by CYP2C9 and CYP3A4 in humans, suggesting promising potential for clinical development.

What Problem Does This Paper Address?

Triple-negative breast cancer (TNBC) remains a significant challenge due to limited effective treatment options and a high mortality rate. The Hedgehog (Hh) signaling pathway is implicated in TNBC development, making it a promising therapeutic target. TPB15, a novel smoothened inhibitor of this pathway, has shown preclinical efficacy and low toxicity. However, before it can advance to clinical trials, a thorough understanding of its pharmacokinetic profile, including how it's absorbed, distributed, metabolized, and excreted (ADME) across different species, is crucial. This is particularly important because drug metabolism and protein binding can vary significantly between preclinical animal models and humans, potentially impacting efficacy and safety predictions. This paper aims to bridge this knowledge gap by characterizing TPB15's plasma protein binding, metabolic stability, and metabolic pathways across mice, rats, dogs, monkeys, and humans.

Methods

The researchers employed a multi-faceted approach to assess TPB15's pharmacokinetic characteristics:

  • Plasma Protein Binding (PPB): The ultrafiltration method was used to determine the extent to which TPB15 binds to plasma proteins in samples from various species. This is a standard technique for quantifying this crucial parameter.
  • Plasma Stability: TPB15 was incubated in plasma from different species over a 120-minute period to assess its stability. This helps understand how well the drug remains intact in the bloodstream.
  • Metabolic Stability in Liver Microsomes: Liver microsomes (containing key drug-metabolizing enzymes) from each species were used to incubate TPB15. This allowed for the determination of its metabolic stability and the calculation of parameters like elimination half-life ($t_{1/2}$) and intrinsic clearance ($CL_{int}$).
  • Metabolic Enzyme Phenotyping: In human liver microsomes, selective CYP450 inhibitors were used to identify which specific enzymes were responsible for TPB15 metabolism. This is a standard approach to pinpointing the key players in drug metabolism.
  • Metabolite Identification: High-resolution mass spectrometry (QTRAP 4000) was employed to identify potential metabolites of TPB15 formed in human liver microsomes. This technique allows for the detection and characterization of breakdown products of the drug.

Datasets

Not discussed in the paper. The study utilized synthesized TPB15 and commercially sourced plasma and liver microsomes from various species.

Key Insights and Ideas

  • Cross-Species Consistency in Protein Binding: TPB15 exhibits remarkably consistent plasma protein binding across all tested species, including humans. This is a significant finding because it suggests that the drug's distribution and availability in the body might be predictable across different models, simplifying preclinical to clinical translation.
  • High Plasma Stability: TPB15 is highly stable in plasma, with minimal degradation observed over 120 minutes. This indicates that the drug is likely to remain intact in circulation for a sufficient duration to exert its therapeutic effect.
  • Species-Specific Metabolic Variability: While protein binding is consistent, TPB15's metabolic stability in liver microsomes shows notable differences between species. This highlights the importance of evaluating drug metabolism in multiple animal models and directly in human systems.
  • CYP2C9 and CYP3A4 as Key Human Metabolizers: The study pinpoints CYP2C9 and CYP3A4 as the primary enzymes responsible for TPB15 metabolism in human liver microsomes. This is crucial information for predicting potential drug-drug interactions (DDIs) with other medications metabolized by these same enzymes.
  • Identification of a Novel Metabolite: A major metabolite of TPB15 was identified, with a molecular weight suggesting an oxidation product. This provides initial insight into the drug's metabolic fate in humans.

Key Results

  • Plasma Protein Binding: TPB15 showed high plasma protein binding across all species, consistently ranging from 80.87% to 82.40%, with no significant concentration dependence or interspecies differences.
  • Plasma Stability: TPB15 remained stable in plasma across all species after 120 minutes, with retention rates between 97.2% and 98.3%.
  • Metabolic Stability: Elimination half-lives ($t_{1/2}$) in liver microsomes varied significantly, from 88 minutes in monkeys to 630 minutes in dogs. Humans had a $t_{1/2}$ of 103.25 minutes. Crab-eating monkeys and humans showed more extensive metabolism compared to other species.
  • Metabolic Enzyme Involvement: In human liver microsomes, TPB15 metabolism was significantly inhibited by sulfaphenazole (CYP2C9 inhibitor) and ketoconazole (CYP3A4 inhibitor), indicating their primary roles.
  • Metabolite: A major metabolite with a molecular weight of 468.9 was identified, suggesting an oxidation reaction.

Limitations and Future Work

The authors acknowledge several limitations:

  • In Vitro vs. In Vivo: The in vitro studies using liver microsomes may not perfectly replicate in vivo conditions.
  • Metabolite Characterization: The functional activity and toxicity of the identified metabolite were not characterized.
  • Phase II Metabolism: Phase II conjugation pathways (e.g., glucuronidation, sulfation) were not investigated.

Future work suggested by the authors includes:

  • In Vivo Validation: Conducting in vivo studies, particularly in primates, to confirm the pharmacokinetic findings.
  • Structural Elucidation: Further structural characterization of the identified metabolite, potentially using NMR, for definitive confirmation.
  • Phase II Metabolism Studies: Investigating the role of phase II enzymes in TPB15 metabolism.
  • Clinical Translation: Leveraging the gathered pharmacokinetic data for animal model selection and predicting drug-drug interactions to facilitate clinical translation.

Summary updated

Abstract

<b>Background/Objectives</b>: Triple-negative breast cancer (TNBC) is a major cause of cancer-related deaths among women. The Hedgehog (Hh) signaling pathway plays a critical role in tumor development, and targeting this pathway may provide new therapeutic opportunities for TNBC. TPB15 is a novel smoothened inhibitor of the Hh pathway, showing promising tumor reduction and low-toxicity properties in vivo/vitro. This study aims to evaluate TPB15's protein binding rates, metabolic stability, and metabolism across different species, including mice, rats, dogs, monkeys, and humans. <b>Methods</b>: TPB15 was synthesized, and its pharmacokinetic profile was assessed. Plasma protein binding was determined using ultrafiltration across multiple species. Stability studies were conducted in plasma and liver microsomes from each species. Additionally, metabolic enzymes in human liver microsomes were characterized with selective CYP450 inhibitors, and high-resolution mass spectrometry was employed to identify metabolites. <b>Results</b>: Plasma protein binding of TPB15 was consistent across species, ranging from 81.5% to 82.4% in humans and rats. After 120 min, TPB15 remained stable in plasma, with retention rates of 97.2-98.3%. The elimination half-life (<i>t</i><sub>1/2</sub>) varied from 88 min in monkeys to 630 min in dogs. In human liver microsomes, metabolism was significantly inhibited by sulfaphenazole and ketoconazole, indicating the involvement of CYP3A4 and CYP2C9 enzymes. TPB15 underwent phase I metabolism, producing a major metabolite with a molecular weight of 468.9. <b>Conclusions</b>: TPB15 demonstrates stable pharmacokinetic properties across species, with consistent protein binding and significant variability in half-life. The observed differences in metabolism are primarily attributed to CYP2C9 and CYP3A4, offering valuable insights into its drug development potential.
BibTeX
@inproceedings{wen2025plasma,
  author = {Dingsheng Wen and Bo‐Yu Chen and Mingqi Deng and Shaoyu Wu and Shuilin Xie},
  title = {{Plasma Protein Binding, Biostability, Metabolite Profiling, and CYP450 Phenotype of TPB15 Across Different Species: A Novel Smoothened Inhibitor for TNBC Therapy}},
  booktitle = {Pharmaceutics},
  year = {2025},
  doi = {10.3390/pharmaceutics17040423},
}
Figure